Skip to content

Accelerating Discoveries with Scailyte's Speed Strength

Accelerating Discoveries with Scailyte's Speed Strength

Accelerating Discoveries with Scailyte’s Speed Strength

Accelerating Discoveries with Scailyte's Speed Strength

In the world of clinical research and development, time is of the essence. Our mission at Scailyte is not just to innovate, but to revolutionize the way we approach discovery. Today, we’re shedding light on our Speed Strength – an edge that transforms the landscape of clinical R&D.

Numbers that Matter: We’re not just about impressive features; we back them up with hard-hitting numbers. Let’s talk about speed! Diana Stoycheva breaks it down: In a conventional single-cell analysis approach, unravelling differences between sample groups can take months. But with ScaiVision, our AI-driven powerhouse, it takes just a month to process data, unveil insights, and identify actionable differences – without the need for extensive clustering and annotation.

From Months to Moments: Picture this – the time you’d usually spend deciphering clusters and annotations, ScaiVision has already deciphered the crucial differences in your data. That’s 6x faster decision-making power. It’s not just efficiency; it’s about swiftly steering your clinical program in the right direction.

Discover, Design, Decide: ScaiVision isn’t just about speed; it’s about informed acceleration. By rapidly identifying actionable insights, it empowers you to make game-changing Go/No Go decisions. This means smarter, quicker, and more informed moves in your clinical journey.

Redesigning Clinical R&D: Our Speed Strength isn’t just about finding differences; it’s about shaping predictive biomarker assays for key clinical outcomes. While conventional methods struggle to keep up, ScaiVision empowers you to make data-driven choices that truly matter for your clinical trials.

De-risking the Future: In the dynamic realm of clinical R&D, speed doesn’t just mean efficiency – it translates to de-risking. With ScaiVision’s speed to discovery, we’re transforming challenges into opportunities, risks into rewards.

At Scailyte, we don’t just keep pace; we set the pace. Our Speed Strength isn’t just a feature; it’s a commitment to propelling you towards success, faster and smarter.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News

01 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

02 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

03 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

04 /04

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News